A study of 523 cases of small cell lung cancer (140 limited-stage cases and 383 extensive-stage cases) reported that both limited- and extensive-stage cancers responded to initial treatment, and the survival period was favorable in the group within the NSE criteria (Zhou et al. 2017). The gene discussed is ENO2; the disease is cancer.